Gamma Glutamyltranspeptidase (GGTase)-positive foci have been used to indicate activity in an initiation/promotion bioassay in rat liver. This rat liver foci bioassay has been proposed for inclusion in tier 2 of a three tier decision tree approach to carcinogenesis testing where it would function to confirm carcinogenic activity. The assay was sensitive to hepatocarcinogens and some nonhepatocarcinogens and was able to distinguish between tumor initiators and tumor promoters. The induction of GGTase-positive foci by methylating agents was associated with the formation of 06-methylguanine and not N-7 methylguanine, which would indicate a mutagenic origin for the foci. The foci once induced did not regress over the life time of the animal. Zonal induction of GGTase activity was induced by some promoters which confounded the scoring of foci incidence. The results to date indicate that the rat liver foci bioassay warrants further validation for inclusion in tier 2 and emphasizes the need to demonstrate the predictive and precursor relationship of GGTase-positive foci to cancer.
INTRODUCTION
The evaluation of the carcinogenic activity of the large number of chemicals and complex mixtures present in the environment appears to be most efficiently accomplished by a three-tier decision tree approach ( Table 1 ; Ref. 1) . In tier 1, samples are screened for potential carcinogenic activity with a minimum number of false negatives. Tier 1 takes advantage of the proposed precursor relationship of mutagenesis to carcinogenesis so that it comprises of bacterial mutagenesis and mammalian cytogenetic assays. In tier 2, the carcinogenic activity is confirmed with a minimal number 
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of both false negatives and false positives. It is important to keep the number of false positives very low in order to minimize the number of chemicals tested in the expensive tier 3 bioassay. The bioassays proposed for tier 2 are listed in Table 2 . Tier 3 supplies data that is required for estimation of carcinogenic potency and is usually a life-time bioassay in both sexes of mice and rats.
In this communication, we discuss some of our results pertaining to the validation of tier 2 and of the rat liver GGTase-positive foci bioassay, a proposed tier 2 assay. The validation of tier 2 requires that the tier possess the ability to distinguish between carcinogens and non-carcinogens with a minimal level of both false negatives and false positives. As part of TOXICOLOGIC PATHOLOGY The rat liver foci bioassay (2-4) being developed and validated, as well as the other bioassays of tier 2 should have the characteristics listed in Table 3 .
The application of the assay in tier 2 for confirmation of carcinogenicity is predicated on the demonstration that the GGTase-positive focus is a preneoplastic lesion. The foci must be demonstrated to be a measure of the extent of initiation and to possess a higher probability of progressing to cancer than liver not containing foci. The assay should be sensitive to a wide range of chemical classes and not simply duplicate the sensitivity of the other assays of tier 2. The assays with redundant sensitivity will be removed from the tier. The ability to distinguish between initiators (i.e., genotoxic carcinogens) and promoters, (i.e., epigenetic carcinogens) is advantageous because the low dose extrapolation models for the estimation of risk are different for genotoxic and epigenetic carcinogens. Information on the mechanism of action of carcinogens is required for estimating carcinogenic potency, especially at the low doses to which humans are exposed. The ability of the rat liver foci bioassay to estimate carcinogenic potency is being evaluated by comparing the response of 24 different chemical classes of carcinogens in the assay to their response in the life-time bioassay. This communication also discusses some of our results in determining the characteristics of the rat liver foci bioassay.
METHODS

Animals
Male Fischer 344, Sprague Dawley and Wistar-Lewis rats were purchased from Charles River Co. (Portage, MI). The animals were maintained in accordance with the standards set forth in the "Guide for Care and Use of Laboratory Animals" of the Institute of Laboratory Animal Research, National Research Council. They were fed Rodent Laboratory Chow (Ralston Purina Co., St. Louis, MO) and given water ad libitum. The rats weighed gm at the start of the experiments.
Determination of GGTase-Positive Foci
Liver sections were scored for the presence of GGTase-positive foci as previously described (5, 6) . Briefly, the sections were stained for GGTase activity according to the procedure of Rutenburg, et al. (7) , counterstained with hematoxylin and scored for focal areas of GGTase activity that contained 9 or more nuclei. FIG. 1 contains an example of one of the GGTase-positive foci.
Protocol of Rat Liver Foci Bioassay
The protocol of the rat liver foci bioassay used in these studies is presented in FIG. 2A and has previously been described in detail (5, 6) . Groups usually consisting of 10 rats each received either a 2/3 partial hepatectomy or a sham operation. Twenty-four hours later the rats received the test substance (initiator) or vehicle control. Seven days after the partial hepatectomy, the rats received 500 ppm sodium phenobarbital in their drinking water for a total of 49 days (promotion). Seven days after the cessation of the phenobarbital treatment the rats were sacrificed.
A second protocol which was used in some of the experiments, is depicted in Fig. 2B . Briefly, the test substance was administered and seven days later the rats started to receive 
PROTOCOLS FOR THE LIVER FOCI BIOASSAY
toxicity and, thereafter. increased back to 500 ppm phenobarbital for five more weeks. The rats were sacrificed one week after the end of 7 weeks of phenobarbital treatment. This second protocol was used to determine whether the test substance was an hepatocarcinogen or whether it required cellular proliferation as provided by a partial hepatectomy in order to induce GGTase-positive foci.
RESULTS AND DISCUSSION
Conditions of the Bioassay
The effect of strain variations on diethylnitrosamine (DENA) initiation of GGTasepositive foci is presented in Table 4 . In the protocol consisting of partial hepatectomy 24 hours prior to the administration of the DENA. the incidence of GGTase-positive foci in Fischer 344. Sprague-Dawley and WistarLewis rats varied between 11 and 13 foci/em" and was not significantly different for any strain. However, while the background level (water vehicle followed by phenobarbital promotion) in Sprague-Dawley and Wistar-Lewis was zero. the Fischer 344 rat exhibited a significant background level of foci. When the partial hepatectomy was delayed until 14 days after the DENA. the induced incidence of foci was less than when the partial hepatectomy was performed 24 hrs prior to the DENA. This confirmed the previously demonstrated ability of partial hepatectomy when performed prior to the administration of a carcinogen to increase the extent of induction of altered foci 500 ppm sodium phenobarbital in their drinking water. Seven days from the beginning of the phenobarbital treatment. the rats received either a 2/3 partial hepatectomy or a sham operation. For one week after the partial hepatectomy, the phenobarbital concentration was decreased to 100 ppm due to increased 
Initiators of GGTase-Positive Foci
The dose-response relationship of DENA initiation of GGTase-positive foci is presented in FIG. 3 . The figure contains the results of two dose-response studies performed approximately 2 years apart. The response to DENA in both studies was very similar and demonstrated a biphasic relationship of dose to incidence of foci. The initial phase exhibited a sharp increase in the incidence of foci as the dose was increased followed by a second phase that demonstrated a much slower rate of increase in foci incidence with dose. In both studies, the change to the decreased re- The dose-response relationship of dimethylhydrazine (DMH) initiation of GGTase-positive foci is presented in FIG. 4 . DMH increased the incidence of foci in a manner that appeared to be linearly related to dose between 0.015 and 1.0 mmole/kg bd wt.
The results obtained in our laboratory of the evaluation of different chemicals in the rat liver foci bioassay are presented in (8-10). As in the other protocol, the incidence of DENA induced foci was not different in any of the strains and the background incidence was only significant in Fischer 344. Becausevof the high background incidence of GGTase-positive foci in Fischer 344 rats and the convenience, supply and historical use in hepatic biochemical studies of Sprague-Dawley rats, we decided to use Sprague-Dawley rats in the validation of the rat liver foci bioassay.
The effect of the solvent vehicle on 7,12-dimethylbenz(a)anthracene (DMBA) initiation of GGTase-positive foci is presented in Table 5 . The administration of DMBA in corn oil resulted in a dose related increase in GGTase-positive foci between 0.0375 to 0.3 mrnole/kg bd wt. The administration of 0.3 mmole/kg bd wt. of DMBA as a fine suspension in either corn oil or tricaprylin resulted in the same increased incidence of foci. When this same dose of DMBA was administered dissolved in dimethylsulfoxide (DMSO) there was no significant increase in foci. Further studies are in progress to attempt to explain why DMBA was inactive when administered in DMSO. has been greatly exaggerated and is in reality a very small part of the time required for the neoplastic progression from the initial effect of the carcinogen to the occurrence of cancer.
---Initiation ----. -+ week regimen of the test substance usually administered in the diet or drinking water; 4) waiting another week; 5) sacrificing the animals and 6) evaluating the liver for the induction of GGTase-positive foci. The result of the group that received both the DENA and the test substance is compared to the sum of the control groups that received only the DENA or the test substance. A greater incidence of GGTase-positive foci in the group that received both DENA and test substance compared to both control groups indicates that the test substance has the potential to be a tumor promoter.
Relationship of CCTase-Positive Foci to Initiation and Neoplasia
The events involved with initiation of chemical carcinogenesis are presented in FIG. 5. Chemical carcinogenesis is postulated to be initiated by the covalent binding of an initiator or metabolite to DNA. Fixation of the alteration in the genome occurs when the alteration is transcribed into a daughter strand. The alteration can be expressed in the transformed cell as a change in the phenotype and upon a few rounds of cellular replication can be observed as a focus of cells possessing an altered phenotype, i.e., altered focus. The altered focus is the earliest observable evidence of initiation so that the extent of altered foci formation would be a good estimate of the extent of initiation.
The induction of GGTase-positive foci by methylating agents has been shown to require their binding to DNA in a form that produces a mutation (11) . The formation of 0 -methylguanine but not N-7 methylguanine by meth-: The bioassay detected the carcinogenic activity of some hepatocarcinogens and some chemicals for which the liver is not a major target organ. The non-liver carcinogens that were detected include azoserine, benzo(a)pyrene, DMBA, MNNG, MNU and urethane. Non-carcinogenic analogues of carcinogens, i.e., aflatoxin B 2 and benzo(e)-pyrene were negative in the bioassay. The assay also did not detect carcinogens such as benzene, bromoform, p-dioxane, lead acetate and 2,4,6-trichlorophenol whose mechanism of action might be epigenetic and not genotoxic. The genotoxic carcinogens MMS, B-propiolactone and safrole were also not detected. The rat liver foci bioassay appears to be sensitive to initiators of hepatocarcinogenesis and to some but not all initiators of carcinogenesis in other target organs.
Distinction Between Initiators and Promoters
The rat liver foci bioassay can be modified in order to test for tumor promoting activity (6) . Briefly, the protocol for demonstrating tumor promoting activity of a test substance consists of 1) administering a known initiator, i.e., 0.6 mmole/kg bd wt. DENA; 2) waiting one week; 3) placing the animals on a seven ylating agents has been demonstrated to result in rnispairing of guanine during DNA transcription and to be associated with the carcinogenic activity of the methylating agents (12) (13) (14) (15) (16) (17) . It has been postulated that initiation (transformation) of a cell occurs upon transcription of DNA containing 06-methylguanine. Clonal growth of the transformed cell would result in the appearance of an altered focus. The formation of 06-methylguanine but not N-7 methylguanine was required for the formation of GGTase-positive foci (Table 7) . This requirement of foci formation for a mutagenic event is indirect evidence that GGTase-positive foci originate from transformed cells and are pre neoplastic lesions.
The preneoplastic nature of the GGTasepositive foci is also supported by their stability. Under the conditions of our protocol consisting of DENA initiation and phenobarbital promotion, the foci do not regress once they have appeared (18) . Scherer and Emmelot (8) and Kitagawa and Sugano (19) have demon-
strated that DENA induced ATPase deficient foci do not regress with time up to and including the appearance of cancer. On the other hand, in other models two types of neoplastic (hyperplastic) nodules that are GGTase-positive have been described in rats, of which one type regressed and the other persisted (20) .
However, in the model we have described, the GGTase-positive foci were persistent and were dependent upon a mutagenic alteration in the DNA, both of which are consistent with a precursor role of the focus to liver cancer. The rather low probability of a focus progressing to cancer has been previously discussed (2) . This low probability could be caused by the necessity for more than one rare event (mutation) in the progression of cancer. The induction of foci measures only the first rare event which results in initiation. Subsequent to foci formation, two other rare events occur: 1) the transition of the foci to a neoplastic nodule and 2) the transition of the nodule to hepatocellular carcinoma. The low probability of the occurrence of these two transitional events results in the low probability of a focus progressing to cancer. Further studies are required to assess the quantitative relationship of the stepwise progression of focus to neoplastic nodule and to cancer. A rat liver initiation/promotion bioassay that employs GGTase-positive foci as an endpoint is being developed and validated for tier 2 of a three tier decision tree approach for carcinogenesis testing. The assay appears to 6). These lesions are distinct from the GGTase-positive focus in that they are 1) limited to zone 1; 2) not spherical but rather elongated ellipsoids that follow the line between two triads; 3) present in most if not all of the zone 1 in a section; and 4) reversible. The zonal lesion is probably induced in response to either zone 1 toxicity and/or bile duct proliferation (bile ducts normally possess GGTase activity). Chemicals that have demonstrated induction of zonal GGTase activity include both tumor promoters and initiators and are listed in Table 8 . Two halogenated hydrocarbons, bromobenzene and carbon tetrachloride, which cause central lobular necrosis did not induce GGTase activity. The extent of zonal induction by some chemicals such as mestranol, was so great that when the chemical was being tested for promoting activity and was administered up to the time of sacrifice, it prevented the evaluation of the slide for GGTase-positive foci. Delaying sacrifice for seven days following the termination of the promotion regimen did not alleviate this situation sufficiently to permit the evaluation of the slides. be sensitive to hepatocarcinogens and to some but not all non-hepatocarcinogens. The assay can also distinguish between tumor initiators and tumor promoters. The assay appears useful in confirmation of carcinogenic activity and in screening for tumor promoters. However, the use of GGTase-positive foci as the determinant of the assay requires the, as yet unproven, demonstration that the foci are preneoplastic and can be employed to estimate carcinogenic potency. The presence of foci does demonstrate that initiation has occurred and does predict a higher than normal probability that cancer will occur. A confounding situation in the assessment of some chemicals for tumor promoting activity was the zonal induction of GGTase activity by the chemicals.
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